check_circleStudy Completed

BAY 43 9006 in combination with doxorubicin chemotherapy in patients

Trial purpose

Primary objective: To define the safety profile of continuously administered
sorafenib in combination with 3-weekly administrations of doxorubicin in subjects with advanced, refractory solid tumors;
Secondary objectives were
• To evaluate the pharmacokinetics and pharmacodynamics of sorafenib in combination with doxorubicin and vice versa;
• To determine the objective tumor response rate including complete and partial response rates based on WHO criteria.

Key Participants Requirements

Sex

N/A

Age

33 - 78 Years
  • -

  • -

Trial summary

Enrollment Goal
54
Trial Dates
September 2002 - March 2008
Phase
Phase 1
Could I Receive a placebo
N/A
Products
Nexavar (Sorafenib, BAY43-9006)
Accepts Healthy Volunteer
No

Trial design

Trial Type
Interventional
Intervention Type
N/A
Trial Purpose
N/A
Allocation
N/A
Blinding
N/A
Assignment
N/A
Trial Arms
N/A